Press release
DHODH Inhibitor Pipeline Drugs Report 2025: Comprehensive Analysis of Drug Development, Clinical Trials, and Strategic Industry Outlook
Curious about the latest updates in the DHODH Inhibitor Pipeline? Click here to explore the therapies and trials making headlines @ DHODH Inhibitor Pipeline Outlook Report [https://www.delveinsight.com/sample-request/dihydroorotate-dehydrogenase-dhodh-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the DHODH Inhibitor Pipeline Report
* DelveInsight's DHODH Inhibitor Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for DHODH Inhibitor treatment.
* The leading DHODH Inhibitor Companies, such as Sanofi, Immunic, PTC Therapeutics, Clear Creek Bio, EyeGate Pharma, ASLAN Pharmaceuticals, Medicines for Malaria Venture, and others.
* Promising DHODH Inhibitor Therapies such as RP7214, IMU-838, PTC 299, and others.
Want to know which companies are leading innovation in DHODH Inhibitor? Dive into the full pipeline insights @ DHODH Inhibitor Clinical Trials Assessment [https://www.delveinsight.com/sample-request/dihydroorotate-dehydrogenase-dhodh-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The DHODH Inhibitor Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The DHODH Inhibitor Pipeline Report also highlights the unmet needs with respect to the DHODH Inhibitor.
DHODH Inhibitor Overview
Dihydroorotate dehydrogenase (DHODH), a novel enzyme, involved in the biosynthesis of uridine. Dihydroorotate dehydrogenases are grouped into Class 1 and Class 2, according to sequence similarity, subcellular location and substrate preference. This protein is a mitochondrial protein located on the outer surface of the inner mitochondrial membrane (IMM). DHODH enzyme is proven to play an active role in cancer and immunological disorders such as Acute Myeloid Leukemia, Rheumatoid Arthritis, and Multiple Sclerosis. Inhibitors of DHODH block the synthesis of pyrimidine-based nucleotides and are known to potentially possess wide applications as chemotherapeutic agents. Suppression of the DHODH enzyme in humans is a proven treatment method for immune disorders, especially cancer, RA (Leflunomide) and multiple sclerosis (Teriflunomide). There are a number of clinical trials underway for COVID-19 Treatment using DHODH inhibitors.
DHODH Inhibitor Emerging Drugs Profile
* IMU-838: Immunic
IMU-838 is a small molecule, oral tablet formulation based investigational drug that inhibits dihydroorotate dehydrogenase (DHODH) enzyme. IMU-838 is under clinical development for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. The drug is in Phase II/III clinical evaluation for the treatment of COVID 2019 infections.
* PTC 299: PTC Therapeutics
Emvododstat (formerly PTC 299) is an oral, small molecule tablet that inhibits the cellular enzyme DHODH. The drug is in Phase II/III clinical studies for COVID 2019 infections and in Phase I for Acute myeloid leukaemia.
If you're tracking ongoing DHODH Inhibitor Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ DHODH Inhibitor Treatment Drugs [https://www.delveinsight.com/sample-request/dihydroorotate-dehydrogenase-dhodh-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The DHODH Inhibitor Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of DHODH Inhibitor with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for DHODH Inhibitor Treatment.
* DHODH Inhibitor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* DHODH Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the DHODH Inhibitor market.
DHODH Inhibitor Companies
Sanofi, Immunic, PTC Therapeutics, Clear Creek Bio, EyeGate Pharma, ASLAN Pharmaceuticals, Medicines for Malaria Venture and others.
DHODH Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Oral
* Parenteral
* Subcutaneous
* Topical
* Molecule Type
DHODH Inhibitor Products have been categorized under various Molecule types such as
* Vaccines
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Product Type
From emerging drug candidates to competitive intelligence, the DHODH Inhibitor Pipeline Report covers it all - check it out now @ DHODH Inhibitor Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/dihydroorotate-dehydrogenase-dhodh-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the DHODH Inhibitor Pipeline Report
* Coverage- Global
* DHODH Inhibitor Companies- Sanofi, Immunic, PTC Therapeutics, Clear Creek Bio, EyeGate Pharma, ASLAN Pharmaceuticals, Medicines for Malaria Venture and others.
* DHODH Inhibitor Therapies- RP7214, IMU-838, PTC 299 , and others.
* DHODH Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* DHODH Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the DHODH Inhibitor Treatment landscape in this detailed analysis @ DHODH Inhibitor Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/dihydroorotate-dehydrogenase-dhodh-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Dihydroorotate Dehydrogenase (DHODH) Inhibitor - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Dihydroorotate Dehydrogenase (DHODH) Inhibitor Collaboration Deals
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II/III)
* IMU-838: Immunic
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* PP 001: EyeGate Pharma
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* MMV-1793609: Medicines for Malaria Venture
* Drug profiles in the detailed report.....
* Inactive Products
* Dihydroorotate Dehydrogenase (DHODH) Inhibitor Key Companies
* Dihydroorotate Dehydrogenase (DHODH) Inhibitor Key Products
* Dihydroorotate Dehydrogenase (DHODH) Inhibitor- Unmet Needs
* Dihydroorotate Dehydrogenase (DHODH) Inhibitor- Market Drivers and Barriers
* Dihydroorotate Dehydrogenase (DHODH) Inhibitor- Future Perspectives and Conclusion
* Dihydroorotate Dehydrogenase (DHODH) Inhibitor Analyst Views
* Dihydroorotate Dehydrogenase (DHODH) Inhibitor Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dhodh-inhibitor-pipeline-drugs-report-2025-comprehensive-analysis-of-drug-development-clinical-trials-and-strategic-industry-outlook]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/dihydroorotate-dehydrogenase-dhodh-inhibitor-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release DHODH Inhibitor Pipeline Drugs Report 2025: Comprehensive Analysis of Drug Development, Clinical Trials, and Strategic Industry Outlook here
News-ID: 4204547 • Views: …
More Releases from ABNewswire
Dr.Kumar Elevates Breast Cancer Recovery with Integrative Oncology at LifeWellMD
Board Certified Oncologist, Harvardtrained Acupuncturist and Functional Medicine expert, Dr.Kumar expands holistic breast cancer recovery services at LifeWellMD in NorthPalmBeach and PortSt.Lucie. By integrating acupuncture, nutrition, stress modulation, and photobiomodulation, he helps patients heal beyond conventional care as Breast Cancer Awareness Month concludes.
North Palm Beach, FL - October 30, 2025 - In closing this year's BreastCancerAwarenessMonth, LifeWellMD spotlights a groundbreaking approach to women's cancer recovery led by Dr.Kumar, a Harvardtrained…
Airbnb just quietly changed the rules and the impacts are huge
Image: https://www.abnewswire.com/upload/2025/10/d150a5e744d73984478ce5098485ab3e.jpg
Starting Sept 8th, Airbnb has radically altered the payment terms for all hosts. What was in the little change with huge impacts? How does this impact every property owner? Will it still be profitable for owners to use Airbnb? What are the three changes and what should you do?
What "small"changes did Airbnb implement that will have huge impacts?
Without much fanfare or reporting, Airbnb just crammed down some huge changes…
Celebrated for Dependable Results - Powell's Plumbing & Air Tops Local Lists for …
When a system starts showing signs of wear, timely replacement can prevent costly repairs and unexpected breakdowns. For homeowners searching for water heater replacement near me, Powell's Plumbing & Air has become the trusted name in Greenwood Estates and throughout Wilmington.
A reliable water heater is essential for everyday comfort, from hot showers and clean dishes to efficient laundry cycles. When a system starts showing signs of wear, timely replacement can…
Suncheon Becomes First Korean Municipality to Join the International Union for C …
City Delegation Attends 24th World Conservation Congress as VIP, Opening Global Platform to Share Its Eco-City Model.
Image: https://www.abnewswire.com/upload/2025/10/99d86112f71da38b0277d839c4dcbd2a.jpg
Image: On October 9 in Abu Dhabi, IUCN Deputy Director General Stewart Maginnis presented the membership certificate to Suncheon Mayor Roh Kwan-kyu. /Courtesy of Suncheon City
The city of Suncheon has become the first basic-level local government in South Korea to join the International Union for Conservation of Nature (IUCN) and has dispatched an…
More Releases for DHODH
Online Transcription Software And Service Market by Type and Application Set for …
New Jersey, US State: "The global Reference Check Platform market in the Information Technology and Telecom category is projected to reach USD 2.5 billion by 2031, growing at a CAGR of 9.5% from 2025 to 2031. With rising industrial adoption and continuous innovation in Information Technology and Telecom applications, the market is estimated to hit USD 1.2 billion in 2024, highlighting strong growth potential throughout the forecast period."
Online Transcription Software…
Homomorphic Encryption Market by Type and Application: Rapid Growth Projected fr …
New Jersey, US State: "The global Homomorphic Encryption market in the Information Technology and Telecom category is projected to reach USD 8.4 billion by 2031, growing at a CAGR of 30% from 2025 to 2031. With rising industrial adoption and continuous innovation in Information Technology and Telecom applications, the market is estimated to hit USD 1.2 billion in 2024, highlighting strong growth potential throughout the forecast period."
The Homomorphic Encryption market…
Global Optical Module For 5g Market by Type and Application - Strong 15.2% CAGR …
New Jersey, US State: "The global Optical Module For 5g market in the Information Technology and Telecom category is projected to reach USD 8.2 billion by 2031, growing at a CAGR of 15.2% from 2025 to 2031. With rising industrial adoption and continuous innovation in Information Technology and Telecom applications, the market is estimated to hit USD 2.5 billion in 2024, highlighting strong growth potential throughout the forecast period."
The optical…
Relapsing-Remitting Multiple Sclerosis Pipeline Insight 2025: Advancing Toward R …
Relapsing-Remitting Multiple Sclerosis (RRMS), the most common MS form, drives active R&D as companies seek safer, more effective, and potentially curative therapies. Affecting 85% of initial MS cases, RRMS involves episodic neurological symptoms with recovery periods. While current disease-modifying therapies (DMTs) like ocrelizumab and fingolimod offer expanded options, challenges remain in long-term efficacy, safety, and halting disease progression.
DelveInsight's "Relapsing-Remitting Multiple Sclerosis - Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/relapsing-remitting-multiple-sclerosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" reveals a vibrant pipeline…
Relapsing-Remitting Multiple Sclerosis Pipeline Appears Robust With 20+ Key Phar …
DelveInsight's, "Relapsing-Remitting Multiple Sclerosis Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Relapsing-Remitting Multiple Sclerosis pipeline landscape. It covers the Relapsing-Remitting Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Relapsing-Remitting Multiple Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with…
Dihydrowhey Dehydrogenase (DHODH) Inhibitor Market Recent Trends, In-depth Analy …
Delving into the Dihydrowhey Dehydrogenase (DHODH) Inhibitor industry, the Dihydrowhey Dehydrogenase (DHODH) Inhibitor Market report emerges as a specialised and extensive study centring on the global market trend analysis. With a particular emphasis on the Dihydrowhey Dehydrogenase (DHODH) Inhibitor market, this report offers a comprehensive overview, featuring a meticulous segmentation based on product type, form, and distribution channel. Projections indicate a steep growth trajectory for the global Dihydrowhey Dehydrogenase (DHODH)…
